AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26914111 — intervention group
Group type: EXPERIMENTAL
Intervention: One grade 'A' embryo
Number of subjects: 761
Study 26914111 — intervention group
Group type: EXPERIMENTAL
Intervention: Two grade 'A' embryos
Number of subjects: 761
Study 26914111 — intervention group
Group type: COMPARATOR
Intervention: One grade 'A' plus one grade 'B' embryo
Number of subjects: 761
Study 26914111 — intervention group
Group type: COMPARATOR
Intervention: One grade 'B' embryo
Number of subjects: 761
Study 26914111 — intervention group
Group type: COMPARATOR
Intervention: Two grade 'B' embryos
Number of subjects: 761
Study 24686825 — intervention group
Group type: EXPERIMENTAL
Intervention: Triadic gaze (TG) treatment twice weekly with a speech‐language pathologist for 29 sessions over 17 weeks
Number of subjects: 18
Study 24686825 — intervention group
Group type: COMPARATOR
Intervention: Standard practice from birth‐to‐three therapists
Number of subjects: 18
Study 23118850 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional and Social Mind Training Group (ESM)
Number of subjects: 74
Study 23118850 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy Group (CBT)
Number of subjects: 74
Study 20880642 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0
Study 20880642 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 20880642 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 0
Study 20880642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study 20880642 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 20880642 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural menopausal supplements and diets rich in isoflavones
Number of subjects: 0
Study 20880642 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine, fluoxetine, bupropion
Number of subjects: 0
Study 20880642 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine and nefazodone
Number of subjects: 0
Study 18035078 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (up to 8 days)
Number of subjects: 3060
Study 18035078 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) (48 hours)
Number of subjects: 3060
Study 16192448 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-microg dose of technetium-99m-labeled monodisperse albuterol aerosols with particle sizes of 1.5 microm, 3 microm, and 6 microm
Number of subjects: 12
Study 16192448 — intervention group
Group type: COMPARATOR
Intervention: 200 microg metered-dose inhaler (MDI) albuterol
Number of subjects: 12
Study 12270622 — intervention group
Group type: EXPERIMENTAL
Intervention: Moulded isomalt-based tablet (50 mg HCT)
Number of subjects: 0
Study 12270622 — intervention group
Group type: EXPERIMENTAL
Intervention: Moulded isomalt-based lozenge (50 mg HCT)
Number of subjects: 0
Study 12270622 — intervention group
Group type: COMPARATOR
Intervention: Conventional tablet (Dichlotride 50 mg)
Number of subjects: 0
Study 9857997 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 211
Study 9857997 — intervention group
Group type: COMPARATOR
Intervention: No PCI (Control)
Number of subjects: 211
Study 7637152 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-fentanyl continuous infusion (BF-C group)
Number of subjects: 100
Study 7637152 — intervention group
Group type: COMPARATOR
Intervention: Morphine bolus injection (M-S group)
Number of subjects: 100
Study 2474109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg initially, adjusted between 1.25-20 mg)
Number of subjects: 331
Study 2474109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril plus HCT (25 mg)
Number of subjects: 331
Study 2474109 — intervention group
Group type: COMPARATOR
Intervention: Control group (captopril, HCT, atenolol)
Number of subjects: 331
Study 320996 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol proprionate (CP)
Number of subjects: 23
Study 320996 — intervention group
Group type: COMPARATOR
Intervention: Cream base alone
Number of subjects: 23
Study 30953553 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition
Number of subjects: 151
Study 30953553 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Nutrition
Number of subjects: 151
Study 28364509 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant 200 mg
Number of subjects: 112
Study 28364509 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant 100 mg
Number of subjects: 112
Study 28364509 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant 50 mg
Number of subjects: 112
Study 28364509 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant 25 mg
Number of subjects: 112
Study 28364509 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant (all doses)
Number of subjects: 112
Study 28364509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 26925577 — intervention group
Group type: EXPERIMENTAL
Intervention: AAB-003 (0.5, 1, 2, 4, or 8 mg/kg)
Number of subjects: 88
Study 26925577 — intervention group
Group type: EXPERIMENTAL
Intervention: AAB-003 (8 mg/kg)
Number of subjects: 88
Study 26925577 — intervention group
Group type: EXPERIMENTAL
Intervention: AAB-003
Number of subjects: 88
Study 25079882 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse delivered intervention with intensive training on screening for IPV, providing supportive referrals, and assessing health and safety risks.
Number of subjects: 42
Study 25079882 — intervention group
Group type: COMPARATOR
Intervention: Standard of care with a one-day training focused on sensitizing staff to IPV as a health issue and referral cards.
Number of subjects: 42
Study 22527308 — intervention group
Group type: EXPERIMENTAL
Intervention: Bibrocathol 2% eye ointment
Number of subjects: 197
Study 22527308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 19745175 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/day encapsulated fish oil (1.2 g total omega-3: 0.7 g DHA; 0.3 g EPA)
Number of subjects: 102
Study 19745175 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil (combination palm and soy)
Number of subjects: 102
Study 17688396 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 325
Study 15122605 — intervention group
Group type: EXPERIMENTAL
Intervention: Miller vein cuff
Number of subjects: 235
Study 15122605 — intervention group
Group type: COMPARATOR
Intervention: Non-cuffed bypasses
Number of subjects: 235
Study 11260813 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the inter‐cigarette interval
Number of subjects: 20
Study 11260813 — intervention group
Group type: EXPERIMENTAL
Intervention: Selecting easy cigarettes to eliminate
Number of subjects: 20
Study 9626787 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose leucovorin (20 mg/m2/day, days 1 through 5) combined with 5-FU (400 mg/m2/day every 4 weeks)
Number of subjects: 83
Study 9626787 — intervention group
Group type: COMPARATOR
Intervention: High-dose leucovorin (200 mg/m2/day, days 1 through 5) combined with 5-FU (400 mg/m2/day every 4 weeks)
Number of subjects: 83
Study 9626787 — intervention group
Group type: COMPARATOR
Intervention: High-dose leucovorin combined with 5-FU
Number of subjects: 83
Study 7886280 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency physical guidance
Number of subjects: 0
Study 7886280 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency feedback
Number of subjects: 0
Study 7886280 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of results
Number of subjects: 0
Study 7886280 — intervention group
Group type: EXPERIMENTAL
Intervention: Faded relative frequency
Number of subjects: 0
Study 3312283 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized oral progesterone, 200 mg daily
Number of subjects: 5
Study 29921036 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) and lattice CO2 laser treatments
Number of subjects: 50
Study 29921036 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach with scar cream massage and silica gel products
Number of subjects: 50
Study 26910108 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine mesylate (BRC)
Number of subjects: 36
Study 26910108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 25135744 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 SQ HDM SLIT-tablet
Number of subjects: 604
Study 25135744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 604
Study 21782418 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (CRT) (2Gyx25+5FU/leucovorin)
Number of subjects: 207
Study 21782418 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) (2Gyx25)
Number of subjects: 207
Study 20841796 — intervention group
Group type: EXPERIMENTAL
Intervention: Email reminders focused on intervention related content (smoking cessation)
Number of subjects: 0
Study 20841796 — intervention group
Group type: EXPERIMENTAL
Intervention: Email reminders focused on general project announcements
Number of subjects: 0
Study 20841796 — intervention group
Group type: EXPERIMENTAL
Intervention: Email reminders focused on unrelated content (oral cancer prevention)
Number of subjects: 0
Study 20841796 — intervention group
Group type: EXPERIMENTAL
Intervention: Day of the week for sending emails
Number of subjects: 0
Study 18048572 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral unfractionated heparin with sodium N‐[8‐(2‐hydroxybenzoyl) amino]caprylate (salcaprozate sodium, SNAC)
Number of subjects: 16
Study 18048572 — intervention group
Group type: COMPARATOR
Intervention: Parenterally administered unfractionated heparin
Number of subjects: 16
Study 18048572 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral unfractionated heparin with SNAC
Number of subjects: 16
Study 16264035 — intervention group
Group type: EXPERIMENTAL
Intervention: BALF smear
Number of subjects: 230
Study 16264035 — intervention group
Group type: EXPERIMENTAL
Intervention: BALF PCR
Number of subjects: 230
Study 16264035 — intervention group
Group type: EXPERIMENTAL
Intervention: BALF smear and/or PCR
Number of subjects: 230
Study 16264035 — intervention group
Group type: EXPERIMENTAL
Intervention: BALF smear or Mycobacterium tuberculosis complex‐PCR
Number of subjects: 230
Study 16264035 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of BALF smear and Mycobacterium tuberculosis complex‐PCR
Number of subjects: 230
Study 12019380 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic circulatory arrest with retrograde cerebral perfusion
Number of subjects: 42
Study 12019380 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic circulatory arrest alone
Number of subjects: 42
Study 12019380 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 7585864 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 164
Study 7585864 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 164
Study 2223344 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% EMLA cream
Number of subjects: 40
Study 2223344 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream and 1% lignocaine infiltration
Number of subjects: 40
Study 2223344 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA and 0.9% saline infiltration
Number of subjects: 40
Study 2223344 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA and 1% lignocaine infiltration
Number of subjects: 40
Study 353090 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisotropine methyl bromide, 80 mg given orally at 8 P.M.
Number of subjects: 30
Study 353090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 353090 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisotropine methyl bromide
Number of subjects: 30
Study 30702534 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diclofenac potassium (50 mg)
Number of subjects: 60
Study 30702534 — intervention group
Group type: COMPARATOR
Intervention: Intravenous acetaminophen (1 g in 500 ml normal saline over 20 min)
Number of subjects: 60
Study 28826727 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon (DEB) with provisional bare-metal stenting
Number of subjects: 254
Study 28826727 — intervention group
Group type: COMPARATOR
Intervention: Primary stenting with drug-eluting stents (DES)
Number of subjects: 254
Study 26764322 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged Garlic Extract (AGE) 2400 mg/d
Number of subjects: 55
Study 26764322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 23652947 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% retinol
Number of subjects: 41
Study 23652947 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% retinol
Number of subjects: 41
Study 23652947 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 41
Study 21270270 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 17
Study 21270270 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenergic blockade (phentolamine and propranolol)
Number of subjects: 17
Study 21270270 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenergic blockade plus cholinergic blockade (atropine)
Number of subjects: 17
Study 21270270 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion on day 2
Number of subjects: 17
Study 19161864 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (iNO)
Number of subjects: 0
Study 17952474 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative hypnosis
Number of subjects: 70
Study 17952474 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without hypnosis
Number of subjects: 70
Study 15514725 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract of Rhodiola rosea radix
Number of subjects: 0
Study 11703529 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aspirin (75 mg/mL in moisturizer, 5-10 mL, three times a day for 21 days)
Number of subjects: 30
Study 11703529 — intervention group
Group type: COMPARATOR
Intervention: Oral aspirin (375-750 mg three times a day for 21 days)
Number of subjects: 30
Study 9718524 — intervention group
Group type: EXPERIMENTAL
Intervention: Open invitation asking women to telephone the screening unit for another appointment
Number of subjects: 2229
Study 9718524 — intervention group
Group type: COMPARATOR
Intervention: Fixed appointment time
Number of subjects: 2229
Study 8005127 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral enoximone (100 mg t.i.d.)
Number of subjects: 24
Study 8005127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8005127 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral enoximone
Number of subjects: 24
Study 2805771 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg trazodone conventional capsules
Number of subjects: 14
Study 2805771 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg controlled‐release tablets
Number of subjects: 14
Study 2805771 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations of trazodone
Number of subjects: 14
Study 1103708 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol (200 mg twice daily)
Number of subjects: 19
Study 1103708 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 19
Study 31262103 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-induced sleep
Number of subjects: 47
Study 27939053 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) environment with cooperative social feedback
Number of subjects: 26
Study 27939053 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) environment with rejective social feedback
Number of subjects: 26
Study 27939053 — intervention group
Group type: COMPARATOR
Intervention: Virtual reality (VR) environment
Number of subjects: 26
Study 27939053 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 26
Study 24840246 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminotomy
Number of subjects: 1176
Study 24840246 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemilaminectomy
Number of subjects: 1176
Study 24840246 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminectomy
Number of subjects: 1176
Study 24840246 — intervention group
Group type: COMPARATOR
Intervention: Laminectomy with Instrumented Fusion (IF)
Number of subjects: 1176
Study 23880426 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide 300 mg/ml with fixed-dose injection protocol
Number of subjects: 120
Study 23880426 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide 300 mg/ml with body surface area adapted injection protocol
Number of subjects: 120
Study 23880426 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide 370 mg/ml with fixed-dose injection protocol
Number of subjects: 120
Study 23880426 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide 370 mg/ml with body surface area adapted injection protocol
Number of subjects: 120
Study 23880426 — intervention group
Group type: COMPARATOR
Intervention: Non-enhanced PET/CT
Number of subjects: 120
Study 21825259 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily orally until disease progression (PD) occurred
Number of subjects: 143
Study 21825259 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with paclitaxel 200 mg/m2 IV and carboplatin AUC 6 IV on day 1 intercalated with erlotinib 150 mg orally on days 2 through 15 every 3 weeks for four cycles followed by erlotinib 150 mg orally until PD occurred
Number of subjects: 143
Study 21825259 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib alone
Number of subjects: 143
Study 21825259 — intervention group
Group type: COMPARATOR
Intervention: CT + erlotinib
Number of subjects: 143
Study 19741514 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 0
Study 19741514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16700816 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg daily for 5 days)
Number of subjects: 9
Study 15537474 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 242
Study 15537474 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 242
Study 15537474 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 242
Study 11303851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (50 mg/kg/dose every 8 h; ≤ 6 g/day)
Number of subjects: 104
Study 11303851 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (50 mg/kg/dose every 8 h; ≤ 6 g/day)
Number of subjects: 104
Study 11303851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 104
Study 11303851 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 104
Study 11303851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime and Ceftazidime
Number of subjects: 104
Study 9423752 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 100
Study 9423752 — intervention group
Group type: COMPARATOR
Intervention: Narcotics
Number of subjects: 100
Study 7740445 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue factor (RTF)
Number of subjects: 757
Study 7740445 — intervention group
Group type: COMPARATOR
Intervention: Conventional thromboplastin (CT)
Number of subjects: 757
Study 3402097 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic systemic antibiotics
Number of subjects: 130
Study 3402097 — intervention group
Group type: COMPARATOR
Intervention: Non-antibiotic group
Number of subjects: 130
Study 31732485 — intervention group
Group type: EXPERIMENTAL
Intervention: B200PaZ
Number of subjects: 240
Study 31732485 — intervention group
Group type: EXPERIMENTAL
Intervention: BloadPaZ
Number of subjects: 240
Study 31732485 — intervention group
Group type: COMPARATOR
Intervention: HRZE
Number of subjects: 240
Study 31732485 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-susceptible tuberculosis
Number of subjects: 240
Study 31732485 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin-resistant tuberculosis
Number of subjects: 240
Study 28073798 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural monitoring and feedback device (PMF)
Number of subjects: 0
Study 28073798 — intervention group
Group type: COMPARATOR
Intervention: No-feedback control group
Number of subjects: 0
Study 25923552 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy
Number of subjects: 1375
Study 25923552 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1375
Study 22816881 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin 25 mg/day
Number of subjects: 61
Study 22816881 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin 35 mg/day
Number of subjects: 61
Study 22816881 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin 50 mg/day
Number of subjects: 61
Study 20971644 — intervention group
Group type: EXPERIMENTAL
Intervention: Stoopwalking
Number of subjects: 9
Study 20971644 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-point crawling
Number of subjects: 9
Study 20971644 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-point crawling
Number of subjects: 9
Study 20971644 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG findings for knee extensors and flexors during all gait techniques
Number of subjects: 9
Study 20971644 — intervention group
Group type: COMPARATOR
Intervention: Presence or absence of kneepads
Number of subjects: 9
Study 18276652 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 50 mg kg(‐1) i.v. as a bolus and then 15 mg kg(‐1) h(‐1) i.v. by continuous infusion
Number of subjects: 50
Study 18276652 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 50
Study 16949484 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordant treatment allocation
Number of subjects: 611
Study 16949484 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordant treatment allocation
Number of subjects: 611
Study 16949484 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in discordant patients
Number of subjects: 611
Study 16949484 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical judgment
Number of subjects: 611